| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
CDK2 CDK9
CK7 targets cyclin-dependent kinases 2 and 9 (Cdk2/9), which are key regulators of cell cycle progression and transcription. CDK2 is involved in the G1/S transition and DNA replication, while CDK9 regulates transcriptional elongation through phosphorylation of RNA polymerase II. Inhibition of Cdk2/9 by CK7 leads to cell cycle arrest and inhibition of transcription. The compound can also be used for the synthesis of Nek1 inhibitors. |
|---|---|
| ln Vitro |
CK7 demonstrates in vitro activity as a Cdk2/9 inhibitor. It can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. The compound's activity is typically assessed in kinase inhibition assays using purified CDK2 and CDK9 enzymes, as well as in cellular assays measuring cell cycle progression and transcriptional activity. As a Cdk2/9 inhibitor, it is a valuable tool for studying cell cycle regulation.
|
| ln Vivo |
In vivo studies for CK7 have not been extensively documented in the available literature. As a Cdk2/9 inhibitor, it has potential for in vivo applications in cancer research. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound's small molecule properties suggest potential for oral bioavailability and tissue penetration.
|
| Enzyme Assay |
For kinase inhibition assays, CK7 is tested against CDK2 and CDK9 at various concentrations. Kinase activity is measured using radiometric (33P-ATP incorporation) or fluorescence-based methods with appropriate substrates. IC50 values are calculated from dose-response curves. Selectivity profiling is conducted by screening the compound against a panel of related kinases to assess specificity for Cdk2/9.
|
| Cell Assay |
For cellular studies, appropriate cancer cell lines are cultured in appropriate media and treated with CK7 at various concentrations. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CellTiter-Glo assays. Cell cycle analysis is performed using propidium iodide staining and flow cytometry. CDK2 and CDK9 inhibition is assessed by measuring phosphorylation of their substrates by Western blot.
|
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of cancer would be used. CK7 would be administered via appropriate routes at various doses. Tumor volume would be measured, and body weight monitored for toxicity. CDK2/9 inhibition and downstream effects in tumor tissues would be assessed by Western blot. Pharmacokinetic parameters including half-life, clearance, and tissue distribution would be determined. However, detailed in vivo protocols for CK7 have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CK7 have not been fully characterized in the available literature. The compound has a molecular formula of C14H12N6O2S and a molecular weight of 328.35. Purity is 99.72%. It is soluble in DMSO at 12.5 mg/mL (38.07 mM) with ultrasonic and warming to 60°C. Comprehensive PK studies including bioavailability, half-life, protein binding, and tissue distribution are needed.
|
| Toxicity/Toxicokinetics |
CK7 is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a Cdk2/9 inhibitor, it can be used for the synthesis of Nek1 inhibitors BSc5231 and BSc5367. Standard laboratory safety precautions should be followed when handling this compound. Purity is 99.72%.
|
| References | |
| Additional Infomation |
CK7 is a Cdk2/9 inhibitor with molecular formula C14H12N6O2S and molecular weight 328.35. It can be used for the synthesis of Nek1 inhibitors BSc5231 and BSc5367. The compound is used in research for studying cell cycle regulation and kinase signaling pathways. It is for research use only and has not been approved for clinical applications. Purity 99.72%.
|
| Molecular Formula |
C14H12N6O2S
|
|---|---|
| Molecular Weight |
328.35
|
| Exact Mass |
328.074
|
| CAS # |
507487-89-0
|
| PubChem CID |
447961
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.668
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
423
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DYTKVFHLKPDNRW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12N6O2S/c1-8-12(23-13(15)17-8)11-5-6-16-14(19-11)18-9-3-2-4-10(7-9)20(21)22/h2-7H,1H3,(H2,15,17)(H,16,18,19)
|
| Chemical Name |
4-methyl-5-[2-(3-nitroanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 12.5 mg/mL (38.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0455 mL | 15.2277 mL | 30.4553 mL | |
| 5 mM | 0.6091 mL | 3.0455 mL | 6.0911 mL | |
| 10 mM | 0.3046 mL | 1.5228 mL | 3.0455 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
